These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Michalczyk A, Klüter S, Rode HB, Simard JR, Grütter C, Rabiller M, Rauh D. Bioorg Med Chem; 2008 Apr 01; 16(7):3482-8. PubMed ID: 18316192 [Abstract] [Full Text] [Related]
6. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase. McLean LR, Zhang Y, Zaidi N, Bi X, Wang R, Dharanipragada R, Jurcak JG, Gillespy TA, Zhao Z, Musick KY, Choi YM, Barrague M, Peppard J, Smicker M, Duguid M, Parkar A, Fordham J, Kominos D. Bioorg Med Chem Lett; 2012 May 01; 22(9):3296-300. PubMed ID: 22464456 [Abstract] [Full Text] [Related]
9. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. Bhattacharya SK, Aspnes GE, Bagley SW, Boehm M, Brosius AD, Buckbinder L, Chang JS, Dibrino J, Eng H, Frederick KS, Griffith DA, Griffor MC, Guimarães CR, Guzman-Perez A, Han S, Kalgutkar AS, Klug-McLeod J, Garcia-Irizarry C, Li J, Lippa B, Price DA, Southers JA, Walker DP, Wei L, Xiao J, Zawistoski MP, Zhao X. Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7523-9. PubMed ID: 23153798 [Abstract] [Full Text] [Related]
10. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH. Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4720-3. PubMed ID: 19596575 [Abstract] [Full Text] [Related]
11. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J. Cancer Res; 2007 Sep 01; 67(17):7987-90. PubMed ID: 17804707 [Abstract] [Full Text] [Related]
12. Structural biology contributions to tyrosine kinase drug discovery. Cowan-Jacob SW, Möbitz H, Fabbro D. Curr Opin Cell Biol; 2009 Apr 01; 21(2):280-7. PubMed ID: 19208462 [Abstract] [Full Text] [Related]
13. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Verkhivker GM. Biopolymers; 2007 Mar 01; 85(4):333-48. PubMed ID: 17167796 [Abstract] [Full Text] [Related]
15. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors. El-Deeb IM, Park BS, Jung SJ, Yoo KH, Oh CH, Cho SJ, Han DK, Lee JY, Lee SH. Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5622-6. PubMed ID: 19700314 [Abstract] [Full Text] [Related]
17. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. Usui T, Ban HS, Kawada J, Hirokawa T, Nakamura H. Bioorg Med Chem Lett; 2008 Jan 01; 18(1):285-8. PubMed ID: 17983745 [Abstract] [Full Text] [Related]
18. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Ahn YM, Clare M, Ensinger CL, Hood MM, Lord JW, Lu WP, Miller DF, Patt WC, Smith BD, Vogeti L, Kaufman MD, Petillo PA, Wise SC, Abendroth J, Chun L, Clark R, Feese M, Kim H, Stewart L, Flynn DL. Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5793-8. PubMed ID: 20800479 [Abstract] [Full Text] [Related]